UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2307-3
Program Prior Authorization/Medical Necessity
Medication Aklief® (trifarotene) cream
P&T Approval Date 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Aklief (trifarotene) cream is a retinoid indicated for the topical treatment of acne vulgaris in
patients 9 years of age and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Aklief will be approved based on both of the following criteria:
a. Diagnosis of acne vulgaris
-AND-
b. History of failure, contraindication, or intolerance to one of the following:
1) Over-the-counter Differin gel
2) Tretinoin cream (generic Retin-A)
Authorization will be issued for 12 months
B. Reauthorization
1. Aklief will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
© 2025 UnitedHealthcare Services Inc.
1
• Supply limits may be in place.
4. References:
1. Aklief [package insert]. Dallas, TX: Galderma; October 2023.
2. Reynolds, RV, Yeung, H, Cheng, CE, et. al. Guidelines of care for the management of
acne vulgaris. J Am Acad Dermatol. 2024; 90:1006.e1-e30.
Program Prior Authorization/Medical Necessity - Aklief
Change Control
Date Change
6/2023 New program
6/2024 Annual review. Updated initial authorization to 12 months and updated
references.
6/2025 Annual review. No changes.
© 2025 UnitedHealthcare Services Inc.
2